Kimberly-Clark Seeks EU Approval for Kenvue Deal
Analysis based on 6 articles · First reported Aug 28, 2026 · Last updated Aug 28, 2026
The EU approval request is a key regulatory milestone for the $40 billion merger, which would create a consumer goods giant with combined revenues of about $32 billion. Approval is likely to boost Kimberly-Clark's stock and market position, while Kenvue shareholders stand to benefit from the acquisition premium.
Kimberly-Clark has formally requested approval from the International — European Commission for its proposed $40 billion acquisition of Kenvue, the maker of Tylenol and other consumer health brands. The deal, announced in November 2025, is expected to close in the second half of 2026. Kimberly-Clark projects $2.1 billion in annual cost savings and combined annual revenues of roughly $32 billion from the merger. Kenvue, which recently missed Q2 earnings estimates due to tariffs and currency costs, has initiated a restructuring program with about $250 million in pre-tax charges expected in 2026, including a global workforce reduction announced in February.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard